- Conditions
- CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
- Interventions
- Gamunex-C, Xembify
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 7
- States / cities
- Rancho Mirage, California • Coral Springs, Florida • Miami, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Primary Immunodeficiency
- Interventions
- IGSC 20%
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 6 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • North Palm Beach, Florida + 8 more
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- Immune Globulin Intravenous (Human), 10% Solution, Immune Globulin Subcutaneous (Human), 20% Solution
- Biological · Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 16
- States / cities
- Irvine, California • Centennial, Colorado • North Palm Beach, Florida + 13 more
- Conditions
- Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
- Interventions
- Xembify, Placebo
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 7
- States / cities
- Huntington Park, California • St. Petersburg, Florida • Bethesda, Maryland + 4 more
- Conditions
- Primary Immunodeficiency
- Interventions
- IGIV-C 10%, IGSC 20%
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 2 Years to 75 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Santa Monica, California • Denver, Colorado + 17 more
- Conditions
- Healthy Volunteers
- Interventions
- TAK-881
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- Primary Immunodeficiency
- Interventions
- IGSC 20% daily push versus every 2 weeks pump, IGSC 20% daily push versus once a week pump, IGSC 20% daily push versus 2 times per week pump, IGSC 20% 150 mg/kg
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 2 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- South Bend, Indiana • Columbus, Ohio • Oklahoma City, Oklahoma + 1 more